Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia

被引：0
|
作者：
Elena Ceccacci
Saverio Minucci
机构：
[1] European Institute of Oncology,Department of Experimental Oncology and Drug Development Program
[2] University of Milan,Department of Biosciences
来源：
British Journal of Cancer | 2016年 / 114卷
关键词：
leukaemia; histone deacetylases; HDACi; cancer stem cells; APL; epigenetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.
引用
收藏
页码：605 / 611
页数：6
相关论文
共 50 条
  • [1] Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
    Ceccacci, Elena
    Minucci, Saverio
    BRITISH JOURNAL OF CANCER, 2016, 114 (06) : 605 - 611
  • [2] The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
    Li, Guo
    Tian, Yuan
    Zhu, Wei-Guo
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [3] Histone deacetylases: target enzymes for cancer therapy
    Denis Mottet
    Vincent Castronovo
    Clinical & Experimental Metastasis, 2008, 25 : 183 - 189
  • [4] Histone deacetylases: target enzymes for cancer therapy
    Mottet, Denis
    Castronovo, Vincent
    CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 (02) : 183 - 189
  • [5] Interplay between histone deacetylases and autophagy - from cancer therapy to neurodegeneration
    Truee, Oliver
    Matthias, Patrick
    IMMUNOLOGY AND CELL BIOLOGY, 2012, 90 (01): : 78 - 84
  • [6] Histone deacetylases modulate resistance to the therapy in lung cancer
    Contreras-Sanzon, Estefania
    Prado-Garcia, Heriberto
    Romero-Garcia, Susana
    Nunez-Corona, David
    Ortiz-Quintero, Blanca
    Luna-Rivero, Cesar
    Martinez-Cruz, Victor
    Carlos-Reyes, Angeles
    FRONTIERS IN GENETICS, 2022, 13
  • [7] Targeting histone deacetylases for cancer therapy: Trends and challenges
    Liang, Tao
    Wang, Fengli
    Elhassan, Reham M.
    Cheng, Yongmei
    Tang, Xiaolei
    Chen, Wengang
    Fang, Hao
    Hou, Xuben
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (06) : 2425 - 2463
  • [8] Targeting histone deacetylases for cancer therapy: Trends and challenges
    Tao Liang
    Fengli Wang
    Reham M.Elhassan
    Yongmei Cheng
    Xiaolei Tang
    Wengang Chen
    Hao Fang
    Xuben Hou
    Acta Pharmaceutica Sinica B, 2023, (06) : 2425 - 2463
  • [9] Targeting class I histone deacetylases in cancer therapy
    Delcuve, Genevieve P.
    Khan, Dilshad H.
    Davie, James R.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (01) : 29 - 41
  • [10] Histone deacetylases and cancer
    Barneda-Zahonero, Bruna
    Parra, Maribel
    MOLECULAR ONCOLOGY, 2012, 6 (06) : 579 - 589
12345